Ghrelin and Gastric Emptying in Children With Functional Dyspepsia
NCT ID: NCT01591174
Last Updated: 2019-05-20
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
30 participants
Study Classification
OBSERVATIONAL
Study Start Date
2012-05-31
Study Completion Date
2016-04-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this research is to see if there are differences between children who have FD and children without FD in the ability of the stomach to empty food and/or in ghrelin hormone levels before and after eating.
Chronic abdominal pain is the most common persistent pain condition in children and adolescents. One of the most often diagnosed types of abdominal pain is functional dyspepsia (FD). FD is abdominal pain or discomfort (e.g., nausea, bloating) in the upper abdomen that does not get better by having a bowel movement.
One possible explanation for having FD is a delay in the emptying of food from the stomach, or delayed gastric (stomach) emptying. Failing to empty the stomach quickly enough may result in the feeling of being full and cause symptoms of bloating, nausea, vomiting and pain. Further, hormonal changes occur before, during, or after eating food that appear to impact stomach emptying.
One of the hormones that changes with meals is called ghrelin. The relationship between ghrelin and stomach emptying needs to be explored more in children with FD. Better understanding of what causes FD symptoms may help us to improve treatment for this condition.
Chronic abdominal pain is the most common persistent pain condition in children and adolescents. One of the most often diagnosed types of abdominal pain is functional dyspepsia (FD). FD is abdominal pain or discomfort (e.g., nausea, bloating) in the upper abdomen that does not get better by having a bowel movement.
One possible explanation for having FD is a delay in the emptying of food from the stomach, or delayed gastric (stomach) emptying. Failing to empty the stomach quickly enough may result in the feeling of being full and cause symptoms of bloating, nausea, vomiting and pain. Further, hormonal changes occur before, during, or after eating food that appear to impact stomach emptying.
One of the hormones that changes with meals is called ghrelin. The relationship between ghrelin and stomach emptying needs to be explored more in children with FD. Better understanding of what causes FD symptoms may help us to improve treatment for this condition.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Compassionate Use of Domperidone for Refractory Gastroparesis
NCT04699591
GERD
Gastroesophageal Reflux
Gastroparesis
RECRUITING
NA
Melatonin in Pediatric FD Population
NCT04684199
Dyspepsia
COMPLETED
NA
Protease Activated Receptor-2 and Gastrointestinal Dysfunction in Critical Illness
NCT03011151
Gastroparesis
Gastrointestinal Disorder, Functional
Critical Illness
UNKNOWN
Pediatric Gastroparesis Registry
NCT03680820
Gastroparesis
Gastroparesis-like Syndrome
COMPLETED
Pharmacokinetics of Enteral Omeprazole Suspension in Patients With Cerebral Palsy and Mental Retardation
NCT00426595
Gastreoesophageal Reflux Disease
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Functional Dyspepsia (FD) is defined as the presence of persistent or recurrent pain or discomfort centered in the upper abdomen with no evidence of organic disease likely to explain the symptoms.
This pain or discomfort must not be exclusively relieved by defecation or associated with the onset of a change in stool frequency or stool form.
Initially, the FD classification criteria included 3 subtypes: ulcer-like, in which pain is the predominant symptom; dysmotility-like, in which discomfort is the predominant symptom; and, unspecified. In 2006, however, the criteria were revised by the Rome III committees. In adults, the previous FD subtypes were eliminated and replaced by two new subtypes: (i) postprandial distress syndrome (PDS), characterized by postprandial fullness or early satiety; and, (ii) epigastric pain syndrome (EPS), characterized by epigastric pain or burning unrelated to meals. In children, the Rome II subtypes were eliminated completely. Although the Rome III subtypes have only been applied within adult criteria, there also appear to be meaningful associations in children with FD which may support their adoption in later revisions of the criteria. Specifically, both inflammation (reflected by mast cell density) and self reported anxiety and depression appear to be uniquely associated with PDS in children.
FD is a common disorder of the upper gastrointestinal (GI) tract, occurring in 26% to 34% of the general population. FD is present in as many as 80% of children being evaluated for chronic abdominal pain. FD is best explained by a biopsychological model with dysfunction within the brain-gut axis. The model suggests that FD is as a result of interaction between biological (e.g., inflammation, mechanical, or sensory dysfunction), psychological (e.g., anxiety, depression, somatization), and social (e.g., interactions with parents, teachers, or peers) factors, which may be interactive with each other. Delayed gastric emptying is one of the mechanical factors which have been implicated. Other mechanisms are visceral hypersensitivity and impaired gastric fundic accommodation.
Delayed gastric emptying has been shown in up to 66% of children with FD. Most of previous studies in children used solid GE as a measure to explain the function of pyloric emptying. However, liquids GE is a good measure to predict the function of fundic accommodation, visceral hypersensitivity as well as pyloric emptying, in which, all these mechanisms were suggested in the mechanical pathophysiological model of FD specifically PDS subtypes. In order to measure gastric emptying (GE), the 13C-acetate breath test (ABT) has the potential to replace 99mtechnetium colloid-based scintigraphy which is the "gold standard" for measuring GE. ABT has an advantage over scintigraphy in that it is a rapid, technically simple, safe and inexpensive means to assess liquid GE in children. As such, it may be more easily utilized as a diagnostic technique in standard clinical practice.
Gastric motility is mainly regulated by extrinsic autonomic nerves, intrinsic neurons of the stomach, and GI hormones. It is hypothesized that these hormones strongly affect hunger and energy expenditure and may be are altered in dyspeptic disorders affecting gastric motility. Because altered gut-brain interactions may underlie symptom generation in FD and ghrelin is an important gut peptide related to the gut-brain axis, plasma concentrations of ghrelin in patients with FD have been investigated in several studies.
Ghrelin is a motilin-related peptide mainly synthesized and released by A-like cells in the stomach. Ghrelin acts as an endogenous ligand of growth hormone secretagogue receptor (GHSR). Ghrelin receptors are present in the anterior pituitary hypothalamus. There are two forms of ghrelin. The first form is acyl ghrelin, comprising 28 amino acid residues with an n-octanoyl ester at Ser3 that is essential for its biologic activity, which acts as an endogenous ligand of growth hormone secretagogue receptor type 1a (GHS-R1a). Acyl ghrelin is easily and rapidly degraded to the second form, desacyl ghrelin, or smaller fragments.
Functionally, ghrelin level progressively rises during fasting to peak just prior to a meal and fall to its lowest level about an hour after eating. Ghrelin level again starts increasing approximately 2 hours after eating to peak again before the next meal. A close relationship has been documented between ghrelin and gastric motility in rats. In humans, it has been demonstrated that ghrelin increases the gastric emptying rate in healthy, but not in obese, controls. Ghrelin has a well-established role in increasing appetite and food intake. These pieces of evidence have led to speculation that altered ghrelin function may contribute to the disturbed gastric motility and appetite loss seen in FD. Moreover, ghrelin agonist administration is found to have stimulatory effect on appetite in FD patients and idiopathic gastroparesis.
Considering that most symptoms of FD are typically related to food intake, postprandial ghrelin level has been investigated in several studies. It has been shown that fasting ghrelin level, in general, is inversely related to gastric emptying time (i,e., lower fasting ghrelin is associated with greater delay in GE). However, this relation is disrupted in FD patients, as these patients do not demonstrate an increase in fasting ghrelin level. Although results have been somewhat conflicting, some previous studies support a role for ghrelin in FD in adults. Takamori et al. reported that fasting desacyl and total ghrelin levels were significantly lower in FD patients than in controls. Further, fasting and postprandial levels were not significantly different in FD, as compared to a significant drop from fasting to postprandial level seen in controls, which suggests that fasting ghrelin does not increase as expected during fasting in FD patients. Consistent with this, Lee et al. showed that delayed GE has been reported in the majority of adults with FD where abnormally low total pre-prandial ghrelin levels were observed. However, the relationship between FD and ghrelin may differ by FD subtype. Shindo et al. reported that fasting acyl ghrelin levels were significantly lower in PDS adult patients than in healthy volunteers. Further, they demonstrated that Tmax value reflective of GE in PDS patients was significantly higher than in healthy volunteers, as measured using the 13-C (carbon) acetate breath test. These results suggested that acyl ghrelin is more biologically important and might play a role in the pathophysiology of the PDS subtype of FD through its effect on gastric emptying.
Collectively, previous studies suggest a relationship between plasma ghrelin concentration and FD, or FD subtype, in adults. Further, it seems likely that this occurs through the impact of ghrelin on gastric emptying in adults. However, to the best of our knowledge, the role of ghrelin in pediatric FD and it its relation to gastric motility in children has not been previously studied. There is a need to investigate the possible role of ghrelin in its two different forms, as well as its relation to gastric motility, in children with FD as a group and across possible subtypes in order to establish better understanding of the pathophysiology of FD. This study may help to build a mechanical pathway model for FD etiology, explore the pharmacokinetics of the ghrelin hormone, and establish its correlation to liquid gastric emptying. If a relationship is established, future work can explore a potential therapeutic role for ghrelin agonist in FD or specific FD subtypes.
This pain or discomfort must not be exclusively relieved by defecation or associated with the onset of a change in stool frequency or stool form.
Initially, the FD classification criteria included 3 subtypes: ulcer-like, in which pain is the predominant symptom; dysmotility-like, in which discomfort is the predominant symptom; and, unspecified. In 2006, however, the criteria were revised by the Rome III committees. In adults, the previous FD subtypes were eliminated and replaced by two new subtypes: (i) postprandial distress syndrome (PDS), characterized by postprandial fullness or early satiety; and, (ii) epigastric pain syndrome (EPS), characterized by epigastric pain or burning unrelated to meals. In children, the Rome II subtypes were eliminated completely. Although the Rome III subtypes have only been applied within adult criteria, there also appear to be meaningful associations in children with FD which may support their adoption in later revisions of the criteria. Specifically, both inflammation (reflected by mast cell density) and self reported anxiety and depression appear to be uniquely associated with PDS in children.
FD is a common disorder of the upper gastrointestinal (GI) tract, occurring in 26% to 34% of the general population. FD is present in as many as 80% of children being evaluated for chronic abdominal pain. FD is best explained by a biopsychological model with dysfunction within the brain-gut axis. The model suggests that FD is as a result of interaction between biological (e.g., inflammation, mechanical, or sensory dysfunction), psychological (e.g., anxiety, depression, somatization), and social (e.g., interactions with parents, teachers, or peers) factors, which may be interactive with each other. Delayed gastric emptying is one of the mechanical factors which have been implicated. Other mechanisms are visceral hypersensitivity and impaired gastric fundic accommodation.
Delayed gastric emptying has been shown in up to 66% of children with FD. Most of previous studies in children used solid GE as a measure to explain the function of pyloric emptying. However, liquids GE is a good measure to predict the function of fundic accommodation, visceral hypersensitivity as well as pyloric emptying, in which, all these mechanisms were suggested in the mechanical pathophysiological model of FD specifically PDS subtypes. In order to measure gastric emptying (GE), the 13C-acetate breath test (ABT) has the potential to replace 99mtechnetium colloid-based scintigraphy which is the "gold standard" for measuring GE. ABT has an advantage over scintigraphy in that it is a rapid, technically simple, safe and inexpensive means to assess liquid GE in children. As such, it may be more easily utilized as a diagnostic technique in standard clinical practice.
Gastric motility is mainly regulated by extrinsic autonomic nerves, intrinsic neurons of the stomach, and GI hormones. It is hypothesized that these hormones strongly affect hunger and energy expenditure and may be are altered in dyspeptic disorders affecting gastric motility. Because altered gut-brain interactions may underlie symptom generation in FD and ghrelin is an important gut peptide related to the gut-brain axis, plasma concentrations of ghrelin in patients with FD have been investigated in several studies.
Ghrelin is a motilin-related peptide mainly synthesized and released by A-like cells in the stomach. Ghrelin acts as an endogenous ligand of growth hormone secretagogue receptor (GHSR). Ghrelin receptors are present in the anterior pituitary hypothalamus. There are two forms of ghrelin. The first form is acyl ghrelin, comprising 28 amino acid residues with an n-octanoyl ester at Ser3 that is essential for its biologic activity, which acts as an endogenous ligand of growth hormone secretagogue receptor type 1a (GHS-R1a). Acyl ghrelin is easily and rapidly degraded to the second form, desacyl ghrelin, or smaller fragments.
Functionally, ghrelin level progressively rises during fasting to peak just prior to a meal and fall to its lowest level about an hour after eating. Ghrelin level again starts increasing approximately 2 hours after eating to peak again before the next meal. A close relationship has been documented between ghrelin and gastric motility in rats. In humans, it has been demonstrated that ghrelin increases the gastric emptying rate in healthy, but not in obese, controls. Ghrelin has a well-established role in increasing appetite and food intake. These pieces of evidence have led to speculation that altered ghrelin function may contribute to the disturbed gastric motility and appetite loss seen in FD. Moreover, ghrelin agonist administration is found to have stimulatory effect on appetite in FD patients and idiopathic gastroparesis.
Considering that most symptoms of FD are typically related to food intake, postprandial ghrelin level has been investigated in several studies. It has been shown that fasting ghrelin level, in general, is inversely related to gastric emptying time (i,e., lower fasting ghrelin is associated with greater delay in GE). However, this relation is disrupted in FD patients, as these patients do not demonstrate an increase in fasting ghrelin level. Although results have been somewhat conflicting, some previous studies support a role for ghrelin in FD in adults. Takamori et al. reported that fasting desacyl and total ghrelin levels were significantly lower in FD patients than in controls. Further, fasting and postprandial levels were not significantly different in FD, as compared to a significant drop from fasting to postprandial level seen in controls, which suggests that fasting ghrelin does not increase as expected during fasting in FD patients. Consistent with this, Lee et al. showed that delayed GE has been reported in the majority of adults with FD where abnormally low total pre-prandial ghrelin levels were observed. However, the relationship between FD and ghrelin may differ by FD subtype. Shindo et al. reported that fasting acyl ghrelin levels were significantly lower in PDS adult patients than in healthy volunteers. Further, they demonstrated that Tmax value reflective of GE in PDS patients was significantly higher than in healthy volunteers, as measured using the 13-C (carbon) acetate breath test. These results suggested that acyl ghrelin is more biologically important and might play a role in the pathophysiology of the PDS subtype of FD through its effect on gastric emptying.
Collectively, previous studies suggest a relationship between plasma ghrelin concentration and FD, or FD subtype, in adults. Further, it seems likely that this occurs through the impact of ghrelin on gastric emptying in adults. However, to the best of our knowledge, the role of ghrelin in pediatric FD and it its relation to gastric motility in children has not been previously studied. There is a need to investigate the possible role of ghrelin in its two different forms, as well as its relation to gastric motility, in children with FD as a group and across possible subtypes in order to establish better understanding of the pathophysiology of FD. This study may help to build a mechanical pathway model for FD etiology, explore the pharmacokinetics of the ghrelin hormone, and establish its correlation to liquid gastric emptying. If a relationship is established, future work can explore a potential therapeutic role for ghrelin agonist in FD or specific FD subtypes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Functional Dyspepsia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Functional Dyspepsia with PDS
Study participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and Clinics in the Abdominal Pain Clinic (APC)or in the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and have Postprandial Distress Syndrome (PDS).
No interventions assigned to this group
Functional Dyspepsia without PDS
Study participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and clinics (CMH) Abdominal Pain Clinic (APC)or the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and do not have Postprandial Distress Syndrome (PDS).
No interventions assigned to this group
Control Group
Healthy participants 8-17 years of age recruited from internal advertising within Children's Mercy Hospital and Clinics.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All: Participants 8-17 years of age
Exclusion Criteria
* History of upper gastrointestinal surgery or intestinal obstruction.
* History of disease or symptoms suggestive of underlying malabsorption, Inflammatory Bowel Disease (IBD), or Peptic Ulcer Disease (PUD).
* History or evidence of chronic illness requiring regular medical care such as diabetes mellitis (DM), liver, heart, kidney, endocrine, or pulmonary disease and asthma that precludes accurate exhalation into the study breath collection apparatus.
* Any patient with body Mass index (BMI) less than or equal to 10th percentile for age; or equal to or greater than 90th percentile for age.
* Patient and/or parent not able to read English.
* Current pregnancy.
* History of milk allergy.
* Prokinetic or psychotropic medications used within the last 72 hour prior to study.
* Inability to exhale into study breath collection apparatus as directed.
* Recent acute illness that occurs prior to study visit.
* History of disease or symptoms suggestive of underlying malabsorption, Inflammatory Bowel Disease (IBD), or Peptic Ulcer Disease (PUD).
* History or evidence of chronic illness requiring regular medical care such as diabetes mellitis (DM), liver, heart, kidney, endocrine, or pulmonary disease and asthma that precludes accurate exhalation into the study breath collection apparatus.
* Any patient with body Mass index (BMI) less than or equal to 10th percentile for age; or equal to or greater than 90th percentile for age.
* Patient and/or parent not able to read English.
* Current pregnancy.
* History of milk allergy.
* Prokinetic or psychotropic medications used within the last 72 hour prior to study.
* Inability to exhale into study breath collection apparatus as directed.
* Recent acute illness that occurs prior to study visit.
Minimum Eligible Age
8 Years
Maximum Eligible Age
17 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's Mercy Hospital Kansas City
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nadia Hijaz
MD, Fellow, Children's Mercy Hospital, Section of Gastroenterology
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nadia M Hijaz, MD
Role: PRINCIPAL_INVESTIGATOR
Fellow, Children's Mercy Hospital, Section of Gastroenterology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Mercy Hospital
Kansas City, Missouri, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006 Apr;130(5):1377-90. doi: 10.1053/j.gastro.2006.03.008. No abstract available.
Reference Type
BACKGROUND
Suzuki H, Nishizawa T, Hibi T. Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. J Gastroenterol. 2006 Jun;41(6):513-23. doi: 10.1007/s00535-006-1847-5.
Reference Type
BACKGROUND
Akamizu T, Iwakura H, Ariyasu H, Kangawa K. Ghrelin and functional dyspepsia. Int J Pept. 2010;2010:548457. doi: 10.1155/2010/548457. Epub 2010 Jan 12.
Reference Type
BACKGROUND
Schurman JV, Singh M, Singh V, Neilan N, Friesen CA. Symptoms and subtypes in pediatric functional dyspepsia: relation to mucosal inflammation and psychological functioning. J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):298-303. doi: 10.1097/MPG.0b013e3181d1363c.
Reference Type
BACKGROUND
Castillo EJ, Camilleri M, Locke GR, Burton DD, Stephens DA, Geno DM, Zinsmeister AR. A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol. 2004 Nov;2(11):985-96. doi: 10.1016/s1542-3565(04)00454-9.
Reference Type
BACKGROUND
Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993 Sep;38(9):1569-80. doi: 10.1007/BF01303162.
Reference Type
BACKGROUND
Schurman JV, Friesen CA, Danda CE, Andre L, Welchert E, Lavenbarg T, Cocjin JT, Hyman PE. Diagnosing functional abdominal pain with the Rome II criteria: parent, child, and clinician agreement. J Pediatr Gastroenterol Nutr. 2005 Sep;41(3):291-5. doi: 10.1097/01.mpg.0000178438.64675.c4.
Reference Type
BACKGROUND
Hyams JS, Hyman PE. Recurrent abdominal pain and the biopsychosocial model of medical practice. J Pediatr. 1998 Oct;133(4):473-8. doi: 10.1016/s0022-3476(98)70053-8. No abstract available.
Reference Type
BACKGROUND
Takamori K, Mizuta Y, Takeshima F, Akazawa Y, Isomoto H, Ohnita K, Ohba K, Omagari K, Shikuwa S, Kohno S. Relation among plasma ghrelin level, gastric emptying, and psychologic condition in patients with functional dyspepsia. J Clin Gastroenterol. 2007 May-Jun;41(5):477-83. doi: 10.1097/01.mcg.0000225614.94470.47.
Reference Type
BACKGROUND
Ogiso K, Asakawa A, Amitani H, Inui A. Ghrelin: a gut hormonal basis of motility regulation and functional dyspepsia. J Gastroenterol Hepatol. 2011 Apr;26 Suppl 3:67-72. doi: 10.1111/j.1440-1746.2011.06630.x.
Reference Type
BACKGROUND
Riezzo G, Chiloiro M, Guerra V, Borrelli O, Salvia G, Cucchiara S. Comparison of gastric electrical activity and gastric emptying in healthy and dyspeptic children. Dig Dis Sci. 2000 Mar;45(3):517-24. doi: 10.1023/a:1005493123557.
Reference Type
BACKGROUND
Heyman S. Gastric emptying in children. J Nucl Med. 1998 May;39(5):865-9.
Reference Type
BACKGROUND
Hou XH, Li Q, Zhu L, Xie X, Chen JD. Correlation of gastric liquid emptying with various thresholds of sensation in healthy controls and patients with functional dyspepsia. Dig Dis Sci. 2004 Feb;49(2):188-95. doi: 10.1023/b:ddas.0000017437.20932.8b.
Reference Type
BACKGROUND
Maes BD, Ghoos YF, Geypens BJ, Hiele MI, Rutgeerts PJ. Relation between gastric emptying rate and energy intake in children compared with adults. Gut. 1995 Feb;36(2):183-8. doi: 10.1136/gut.36.2.183.
Reference Type
BACKGROUND
Jones BL, Pearce RE, Abdel-Rahman SM, Friesen CA, James LP, Kearns GL. Characterization of delayed liquid gastric emptying in children by the (13)C-acetate breath test. J Breath Res. 2009 Dec;3(4):047004. doi: 10.1088/1752-7155/3/4/047004. Epub 2009 Nov 27.
Reference Type
BACKGROUND
Braden B, Adams S, Duan LP, Orth KH, Maul FD, Lembcke B, Hor G, Caspary WF. The [13C]acetate breath test accurately reflects gastric emptying of liquids in both liquid and semisolid test meals. Gastroenterology. 1995 Apr;108(4):1048-55. doi: 10.1016/0016-5085(95)90202-3.
Reference Type
BACKGROUND
Hauser B, De Schepper J, Caveliers V, Salvatore S, Salvatoni A, Vandenplas Y. Variability of the 13C-acetate breath test for gastric emptying of liquids in healthy children. J Pediatr Gastroenterol Nutr. 2006 Apr;42(4):392-7. doi: 10.1097/01.mpg.0000215306.40546.17.
Reference Type
BACKGROUND
Barbosa L, Vera H, Moran S, Del Prado M, Lopez-Alarcon M. Reproducibility and reliability of the 13C-acetate breath test to measure gastric emptying of liquid meal in infants. Nutrition. 2005 Mar;21(3):289-94. doi: 10.1016/j.nut.2004.05.027.
Reference Type
BACKGROUND
Gatti C, di Abriola FF, Dall'Oglio L, Villa M, Franchini F, Amarri S. Is the 13C-acetate breath test a valid procedure to analyse gastric emptying in children? J Pediatr Surg. 2000 Jan;35(1):62-5. doi: 10.1016/s0022-3468(00)80015-9.
Reference Type
BACKGROUND
Ueno H, Shiiya T, Nakazato M. Translational research of ghrelin. Ann N Y Acad Sci. 2010 Jul;1200:120-7. doi: 10.1111/j.1749-6632.2010.05509.x.
Reference Type
BACKGROUND
Chanoine JP. Ghrelin in growth and development. Horm Res. 2005;63(3):129-38. doi: 10.1159/000084688. Epub 2005 Mar 24.
Reference Type
BACKGROUND
Tack J, Depoortere I, Bisschops R, Delporte C, Coulie B, Meulemans A, Janssens J, Peeters T. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut. 2006 Mar;55(3):327-33. doi: 10.1136/gut.2004.060426. Epub 2005 Oct 10.
Reference Type
BACKGROUND
Lee KJ, Cha DY, Cheon SJ, Yeo M, Cho SW. Plasma ghrelin levels and their relationship with gastric emptying in patients with dysmotility-like functional dyspepsia. Digestion. 2009;80(1):58-63. doi: 10.1159/000215389. Epub 2009 Jun 3.
Reference Type
BACKGROUND
Shindo T, Futagami S, Hiratsuka T, Horie A, Hamamoto T, Ueki N, Kusunoki M, Miyake K, Gudis K, Tsukui T, Iwakiri K, Sakamoto C. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion. 2009;79(2):65-72. doi: 10.1159/000205740. Epub 2009 Feb 27.
Reference Type
BACKGROUND
Fukuda H, Mizuta Y, Isomoto H, Takeshima F, Ohnita K, Ohba K, Omagari K, Taniyama K, Kohno S. Ghrelin enhances gastric motility through direct stimulation of intrinsic neural pathways and capsaicin-sensitive afferent neurones in rats. Scand J Gastroenterol. 2004 Dec;39(12):1209-14.
Reference Type
BACKGROUND
Trudel L, Tomasetto C, Rio MC, Bouin M, Plourde V, Eberling P, Poitras P. Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. Am J Physiol Gastrointest Liver Physiol. 2002 Jun;282(6):G948-52. doi: 10.1152/ajpgi.00339.2001.
Reference Type
BACKGROUND
Heath RB, Jones R, Frayn KN, Robertson MD. Vagal stimulation exaggerates the inhibitory ghrelin response to oral fat in humans. J Endocrinol. 2004 Feb;180(2):273-81. doi: 10.1677/joe.0.1800273.
Reference Type
BACKGROUND
Lin Z, Eaker EY, Sarosiek I, McCallum RW. Gastric myoelectrical activity and gastric emptying in patients with functional dyspepsia. Am J Gastroenterol. 1999 Sep;94(9):2384-9. doi: 10.1111/j.1572-0241.1999.01362.x.
Reference Type
BACKGROUND
Valera Mora ME, Scarfone A, Valenza V, Calvani M, Greco AV, Gasbarrini G, Mingrone G. Ghrelin does not influence gastric emptying in obese subjects. Obes Res. 2005 Apr;13(4):739-44. doi: 10.1038/oby.2005.83.
Reference Type
BACKGROUND
Wren AM, Bloom SR. Gut hormones and appetite control. Gastroenterology. 2007 May;132(6):2116-30. doi: 10.1053/j.gastro.2007.03.048.
Reference Type
BACKGROUND
Akamizu T, Iwakura H, Ariyasu H, Hosoda H, Murayama T, Yokode M, Teramukai S, Seno H, Chiba T, Noma S, Nakai Y, Fukunaga M, Nakai Y, Kangawa K; FD Clinical Study Team. Repeated administration of ghrelin to patients with functional dyspepsia: its effects on food intake and appetite. Eur J Endocrinol. 2008 Apr;158(4):491-8. doi: 10.1530/EJE-07-0768.
Reference Type
BACKGROUND
Ejskjaer N, Dimcevski G, Wo J, Hellstrom PM, Gormsen LC, Sarosiek I, Softeland E, Nowak T, Pezzullo JC, Shaughnessy L, Kosutic G, McCallum R. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol Motil. 2010 Oct;22(10):1069-e281. doi: 10.1111/j.1365-2982.2010.01519.x. Epub 2010 Jun 28.
Reference Type
BACKGROUND
Tack J, Depoortere I, Bisschops R, Verbeke K, Janssens J, Peeters T. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther. 2005 Nov 1;22(9):847-53. doi: 10.1111/j.1365-2036.2005.02658.x.
Reference Type
BACKGROUND
Ang D, Nicolai H, Vos R, Mimidis K, Akyuz F, Kindt S, Vanden Berghe P, Sifrim D, Depoortere I, Peeters T, Tack J. Influence of ghrelin on the gastric accommodation reflex and on meal-induced satiety in man. Neurogastroenterol Motil. 2009 May;21(5):528-33, e8-9. doi: 10.1111/j.1365-2982.2008.01239.x. Epub 2008 Jan 30.
Reference Type
BACKGROUND
Nishizawa T, Suzuki H, Nomoto Y et al. Enhanced plasma ghrelin levels in patients with functional dyspepsia. Aliment. Pharmacol. Ther. 2006; 24 (Suppl. 4): 104-10. 02.01.12
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ghrelin 12010078
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Gastrointestinal Dysfunction in Children Affected With Mitochondrial Disorders
NCT01137240
COMPLETED
Metoclopramide Pilot Trial
NCT02098915
TERMINATED
PHASE3
Recurrent Abdominal Pain in Children
NCT00526903
COMPLETED
PHASE2
Electrogastrography (EGC) in Premature Infants With Feeding Intolerance
NCT00008736
COMPLETED
PHASE2
Monosodium Glutamate on Gastric Emptying
NCT02745028
WITHDRAWN
NA
Efficacy of Guided Imagery Therapy Mobile Application for Functional Abdominal Pain
NCT06653647
COMPLETED
NA
Bee Honey and Functional Dyspepsia in Children
NCT05209646
COMPLETED
NA
Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain
NCT01269671
WITHDRAWN
PHASE1
Study of Medication for Functional Abdominal Pain in Children
NCT00564525
COMPLETED
PHASE4
Gastrointestinal Dysmotility on Aspiration Risk
NCT05455359
RECRUITING
PHASE4
Effect of Domperidone on Completion Rate of Vedio Capsule Endoscopy
NCT03662113
COMPLETED
NA
MSOT and MRI for Non-invasive Assessment of Intestinal Transit Time in Children With Chronic Bowel Emptying Disorders
NCT06911749
RECRUITING
NA
Domperidone in Refractory Gastroparesis
NCT00760461
TERMINATED
PHASE2
Use of Prokinetics in Early Enteral Feeding in Preterm Infants
NCT01569633
WITHDRAWN
NA
In Vivo Assessment of Histamine Pharmacodynamics
NCT00809692
WITHDRAWN
NA
Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.
NCT00226044
COMPLETED
PHASE3
Domperidone for Relief of Gastrointestinal Disorders
NCT00761254
TERMINATED
NA
The Clinical Manifestation and Prognosis of Pediatric Esophageal Motility Disorders
NCT06629025
COMPLETED
Magnetic Resonance Imaging in Paediatric Constipation
NCT03564249
COMPLETED
NA
Transient Receptor Potential Vanilloid One (TRPV1) Receptor Expression in Children With Retrosternal Pain
NCT00677378
COMPLETED
Three Dietary Regimens in Pre-colonoscopic Bowel Preparation in Children
NCT05609591
COMPLETED
NA
Reducing Pain and Anxiety Through Dietary Fiber Supplementation in Children With Abdominal Pain
NCT04619095
WITHDRAWN
NA
The Effect of Amoxicillin Versus Placebo on Gastrointestinal Motility in Children
NCT01530009
COMPLETED
NA
Clinical Implementation of a Pictographic Constipation Action Plan for Children With Functional Constipation
NCT05437523
COMPLETED
NA
Mechanisms and Management of Infant Dysphagia
NCT02583360
COMPLETED
NA